Search results
Results from the WOW.Com Content Network
Acute use (1–3 days) yields a potency about 1.5× stronger than that of morphine and chronic use (7 days+) yields a potency about 2.5 to 5× that of morphine. Similarly, the effect of tramadol increases after consecutive dosing due to the accumulation of its active metabolite and an increase of the oral bioavailability in chronic use.
After previously discounting a twice-daily version of its weight loss drug due to patients having difficulties tolerating it, Pfizer Inc (NYSE: PFE) moved forward with the once-daily version. On ...
Danuglipron is a small-molecule GLP-1 agonist developed by Pfizer [1] that, in an oral formulation, is under investigation as a therapy for diabetes mellitus. Initial results from a randomized controlled trial indicate that it reduced weight [2] and improved diabetic control. The most commonly reported adverse events were nausea, diarrhea, and ...
(Reuters) -Pfizer plans to move a reworked, once-a-day version of its weight-loss pill danuglipron into clinical trials later this year, the company said on Thursday, after scrapping a twice ...
ADB-BINACA (also known as ADMB-BZINACA using EMCDDA naming standards [1]) is a cannabinoid designer drug that has been found as an ingredient in some synthetic cannabis products. [2] It was originally developed by Pfizer as a potential analgesic, and is a potent agonist of the CB 1 receptor with a binding affinity (K i) of 0.33 nM and an EC 50 ...
Pfizer hasn't yet tapped into the highly lucrative market of diabetes drugs that have recently been increasingly used for weight loss purposes. Pfizer moving forward with once-daily weight-loss ...
The Food and Drug Administration authorization comes one day after the agency cleared a competing drug from Pfizer. As a result, Merck's pill is expected to have a smaller role against the ...
In November 2021, Pfizer signed a license agreement with the United Nations–backed Medicines Patent Pool to allow nirmatrelvir to be manufactured and sold in 95 countries. [25] Pfizer stated that the agreement will allow local medicine manufacturers to produce the pill "with the goal of facilitating greater access to the global population".